• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

莫西沙星口服混悬液的临时配制稳定性。

Stability of extemporaneously prepared moxifloxacin oral suspensions.

作者信息

Hutchinson David J, Johnson Cary E, Klein Kristin C

机构信息

Wegmans School of Pharmacy, St. John Fisher College, Rochester, NY, USA.

出版信息

Am J Health Syst Pharm. 2009 Apr 1;66(7):665-7. doi: 10.2146/ajhp080152.

DOI:10.2146/ajhp080152
PMID:19299374
Abstract

PURPOSE

The stability of extemporaneously prepared moxifloxacin oral suspensions was studied.

METHODS

An oral suspension of moxifloxacin 20 mg/mL was prepared by thoroughly grinding three 400-mg tablets of moxifloxacin in a glass mortar. Thirty milliliters of Ora-Plus and 30 mL of either Ora-Sweet or Ora-Sweet SF were mixed and added to the powder to make a final volume of 60 mL. Three identical samples of each formulation were prepared and placed in 2-oz amber plastic bottles with child-resistant caps and were stored at room temperature (23-25 degrees C). A 1-mL sample was withdrawn from each of the six bottles with a micropipette immediately after preparation and at 7, 14, 28, 60, and 90 days. After further dilution to an expected concentration of 8 microg/ mL with sample diluent, the samples were assayed in duplicate by stability-indicating high-performance liquid chromatography. Stability was defined as the retention of at least 90% of the initial concentration.

RESULTS

At least 99% of the initial moxifloxacin remained throughout the 90-day study period in both preparations. There were no detectable changes in color, odor, taste, and pH and no visible microbial growth in any sample.

CONCLUSION

Extemporaneously compounded suspensions of moxifloxacin 20 mg/mL in a 1:1 mixture of Ora-Plus and Ora-Sweet or Ora-Sweet SF were stable for at least 90 days when stored in 2-oz amber plastic bottles at room temperature.

摘要

目的

研究莫西沙星临时配制口服混悬液的稳定性。

方法

将三片400毫克的莫西沙星片剂在玻璃研钵中充分研磨,制备出浓度为20毫克/毫升的莫西沙星口服混悬液。将30毫升 Ora-Plus与30毫升 Ora-Sweet或 Ora-Sweet SF混合,加入到上述粉末中,最终体积达到60毫升。每种配方制备三个相同的样品,置于带有儿童安全盖的2盎司琥珀色塑料瓶中,室温(23 - 25摄氏度)保存。制备后立即以及在第7、14、28、60和90天,用微量移液器从六个瓶子中各取出1毫升样品。用样品稀释剂进一步稀释至预期浓度8微克/毫升后,通过稳定性指示高效液相色谱法对样品进行双份测定。稳定性定义为至少保留初始浓度的90%。

结果

在整个90天的研究期间,两种制剂中初始莫西沙星的含量至少保留了99%。任何样品的颜色、气味、味道和pH值均未检测到变化,也没有可见的微生物生长。

结论

当在室温下储存在2盎司琥珀色塑料瓶中时,由Ora-Plus与Ora-Sweet或Ora-Sweet SF按1:1混合制成的20毫克/毫升莫西沙星临时配制混悬液至少90天内稳定。

相似文献

1
Stability of extemporaneously prepared moxifloxacin oral suspensions.莫西沙星口服混悬液的临时配制稳定性。
Am J Health Syst Pharm. 2009 Apr 1;66(7):665-7. doi: 10.2146/ajhp080152.
2
Stability of extemporaneously prepared rifaximin oral suspensions.利福昔明口服混悬剂的稳定性。
Am J Health Syst Pharm. 2010 Feb 15;67(4):287-9. doi: 10.2146/ajhp090206.
3
Stability of extemporaneously prepared glycopyrrolate oral suspensions.临时制备的格隆溴铵口服混悬液的稳定性。
Am J Health Syst Pharm. 2011 May 1;68(9):843-5. doi: 10.2146/100247.
4
Stability of extemporaneously prepared sodium phenylbutyrate oral suspensions.临时配制的苯丁酸钠口服混悬液的稳定性。
Am J Health Syst Pharm. 2007 Jul 15;64(14):1513-5. doi: 10.2146/ajhp060450.
5
Stability of extemporaneously prepared rufinamide oral suspensions.临时制备的雷夫酰胺口服混悬液的稳定性。
Ann Pharmacother. 2010 Mar;44(3):462-5. doi: 10.1345/aph.1M647. Epub 2010 Feb 11.
6
Stability of an extemporaneously prepared alcohol-free phenobarbital suspension.临时配制的无醇苯巴比妥混悬液的稳定性
Am J Health Syst Pharm. 2007 Mar 15;64(6):644-6. doi: 10.2146/ajhp060107.
7
Stability of an extemporaneously prepared tadalafil suspension.他达拉非混悬剂的稳定性。
Am J Health Syst Pharm. 2012 Apr 1;69(7):592-4. doi: 10.2146/ajhp110034.
8
Stability of extemporaneously prepared oxandrolone oral suspensions.昂丹司琼口服液的稳定性。
Am J Health Syst Pharm. 2011 Mar 15;68(6):519-21. doi: 10.2146/ajhp100225.
9
Stability of an extemporaneously prepared thalidomide suspension.临用前配制的沙利度胺混悬液的稳定性。
Am J Health Syst Pharm. 2012 Jan 1;69(1):56-8. doi: 10.2146/ajhp110105.
10
Stability of an extemporaneous alcohol-free melatonin suspension.无醇褪黑素混悬液的稳定性。
Am J Health Syst Pharm. 2011 Mar 1;68(5):420-3. doi: 10.2146/ajhp100274.

引用本文的文献

1
CDC Guidelines for the Prevention and Treatment of Anthrax, 2023.2023 年美国疾病预防控制中心炭疽病预防和治疗指南。
MMWR Recomm Rep. 2023 Nov 17;72(6):1-47. doi: 10.15585/mmwr.rr7206a1.
2
Moxifloxacin Pharmacokinetics, Cardiac Safety, and Dosing for the Treatment of Rifampicin-Resistant Tuberculosis in Children.莫西沙星的药代动力学、心脏安全性和剂量用于治疗儿童耐利福平结核病。
Clin Infect Dis. 2022 Apr 28;74(8):1372-1381. doi: 10.1093/cid/ciab641.
3
Acceptability of levofloxacin, moxifloxacin and linezolid among children and adolescents treated for TB.
左氧氟沙星、莫西沙星和利奈唑胺在接受结核病治疗的儿童和青少年中的可接受性。
Int J Tuberc Lung Dis. 2020 Dec 1;24(12):1316-1318. doi: 10.5588/ijtld.20.0544.
4
Photodegradation of moxifloxacin in aqueous and organic solvents: a kinetic study.莫西沙星在水性和有机溶剂中的光降解:一项动力学研究。
AAPS PharmSciTech. 2014 Dec;15(6):1588-97. doi: 10.1208/s12249-014-0184-x. Epub 2014 Aug 20.